MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model

被引：19
|
作者：
Turetschek, K [1 ]
Preda, A
Floyd, E
Shames, DM
Novikov, V
Roberts, TPL
Wood, JM
Fu, YJ
Carter, WO
Brasch, RC
机构：
[1] Univ Calif San Francisco, Dept Radiol, Ctr Pharmaceut & Mol Imaging, San Francisco, CA USA
[2] Univ Vienna, Dept Radiol, A-1090 Vienna, Austria
[3] Pfizer Cent rs, Groton, CT USA
[4] Novartis Pharma AG Ltd, Dept Oncol Res, Basel, Switzerland
来源：
ACADEMIC RADIOLOGY | 2002年 / 9卷
关键词：
D O I：
10.1016/S1076-6332(03)80281-7
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S519 / S520
页数：2
相关论文
共 50 条
  • [21] Therapeutic evaluation of the VEGF receptor tyrosine kinase inhibitor ZD6474 in a murine model of spontaneous colorectal cancer
    Wilkinson, RW
    Ryan, AJ
    Wedge, SR
    Pyrah, ITG
    Mandir, N
    Goodlad, RA
    BRITISH JOURNAL OF CANCER, 2004, 91 : S16 - S16
  • [22] MRI for monitoring breast cancer response to neoadjuvant chemotherapy
    Pires Novais Dias, L.
    Ribeiro, J.
    Batista, E.
    Pinto, D.
    Brito, M. J.
    Vasconcelos, M. A.
    Gouveia, P.
    Sousa, B.
    Volovat, S.
    Chumbo, M.
    Mavioso, C. M.
    Freitas Melro Braghiroli, O.
    Possanzini, M.
    Hernandez, J.
    Alves, C.
    Cardoso, M. J.
    Cardoso, F.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S158 - S159
  • [23] Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
    Roviello, Giandomenico
    Ravelli, Andrea
    Polom, Karol
    Petrioli, Roberto
    Marano, Luigi
    Marrelli, Daniele
    Roviello, Franco
    Generali, Daniele
    CANCER LETTERS, 2016, 372 (02) : 187 - 191
  • [24] A deep-learning model for predicting tyrosine kinase inhibitor response from histology in gastrointestinal stromal tumor
    Kong, Xue
    Shi, Jun
    Sun, Dongdong
    Cheng, Lanqing
    Wu, Can
    Jiang, Zhiguo
    Zheng, Yushan
    Wang, Wei
    Wu, Haibo
    JOURNAL OF PATHOLOGY, 2025, 265 (04): : 462 - 471
  • [25] Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice
    Kang, Seungbum
    Roh, Young-Jung
    Kim, In-Beom
    EXPERIMENTAL EYE RESEARCH, 2013, 112 : 125 - 133
  • [26] Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Philip M. Spanheimer
    Allison W. Lorenzen
    James P. De Andrade
    Mikhail V. Kulak
    Jennifer C. Carr
    George W. Woodfield
    Sonia L. Sugg
    Ronald J. Weigel
    Annals of Surgical Oncology, 2015, 22 : 4287 - 4294
  • [27] Tyrosine-kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Spanheimer, P. M.
    Kulak, M. V.
    Carr, J. C.
    Woodfield, G. W.
    De Andrade, J. P.
    Sugg, S. L.
    Weigel, R. J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S11 - S11
  • [28] Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Spanheimer, Philip M.
    Lorenzen, Allison W.
    De Andrade, James P.
    Kulak, Mikhail V.
    Carr, Jennifer C.
    Woodfield, George W.
    Sugg, Sonia L.
    Weigel, Ronald J.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (13) : 4287 - 4294
  • [29] Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
    Haznedaroglu, Ibrahim C.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
  • [30] A novel tyrosine kinase signaling pathway in human basal breast cancer
    Daly, Roger J.
    Hochgraefe, Falko
    Croucher, David R.
    Zhang, Luxi
    Rickwood, Danny
    Browne, Brigid C.
    Tactacan, Carole
    Raftery, Mark
    CANCER RESEARCH, 2011, 71
12345